IL13RA1: A Potential Drug Target and Biomarker for Cancer and Testis Antigens
IL13RA1: A Potential Drug Target and Biomarker for Cancer and Testis Antigens
IL13RA1 is a protein that is expressed in various tissues throughout the body, including the breast, lung, and gastrointestinal tract. It is a member of the Interleukin-13 receptor family, which is a group of cytokines that play a crucial role in the immune response and inflammation. One of the functions of IL13RA1 is to regulate the activity of natural killer cells, which are a critical part of the immune system that help to fight off cancer cells.
IL13RA1 has also been shown to be involved in the development and progression of testicular cancer, which is the most common form of cancer in young men. Studies have suggested that high levels of IL13RA1 in the testicular tissue may be a predictor of the risk of developing testicular cancer, and that inhibiting the activity of IL13RA1 using drugs or other therapeutic approaches may be a promising strategy for the treatment of this disease.
The Potential Role of IL13RA1 as a Drug Target
IL13RA1 is a potential drug target because of its involvement in the immune response and the development of cancer. One of the ways that IL13RA1 contributes to these processes is by regulating the activity of natural killer cells. Natural killer cells are a type of immune cell that play a critical role in detecting and destroying cancer cells. However, cancer cells can sometimes evade the immune system's defenses by suppressing the activity of natural killer cells.
IL13RA1 has been shown to be involved in the regulation of natural killer cells in various tissues, including the breast and the gastrointestinal tract. Studies have suggested that high levels of IL13RA1 in these tissues may be a risk factor for the development of cancer. Additionally, experiments have shown that inhibiting the activity of IL13RA1 using drugs or other therapeutic approaches can be effective in mouse models of cancer, leading to a reduction in the growth of cancer cells.
The potential benefits of targeting IL13RA1 with drugs or other therapeutic approaches are significant. By inhibiting the activity of IL13RA1, researchers may be able to reduce the risk of cancer progression and improve the overall quality of life for patients. Additionally, targeting IL13RA1 may also have implications for the treatment of other diseases that are characterized by inflammation or immune system dysfunction.
The Potential Role of IL13RA1 as a Biomarker
IL13RA1 has also been shown to be involved in the development and progression of testicular cancer, which is a common form of cancer that affects young men. The detection of IL13RA1 in testicular tissue has been shown to be a sensitive and reliable biomarker for the diagnosis of testicular cancer, with higher levels of IL13RA1 in the testicular tissue associated with a greater risk of developing cancer.
In addition to its potential as a drug target, IL13RA1 has also been shown to be a potential biomarker for the diagnosis and prognosis of testicular cancer. Studies have suggested that IL13RA1 levels in the testicular tissue may be a predictor of the risk of developing cancer, with higher levels of IL13RA1 in the tissue associated with a greater risk of developing testicular cancer. Additionally, research has shown that IL13RA1 levels in the testicular tissue can be used as a biomarker for monitoring the effectiveness of cancer treatments, with a reduction in IL13RA1 levels indicating a treatment effect.
Conclusion
In conclusion, IL13RA1 is a protein that is involved in the immune response and the development of cancer. Its potential as a drug target and biomarker make it an attractive target for researchers to explore for the treatment of cancer and other diseases. The
Protein Name: Interleukin 13 Receptor Subunit Alpha 1
Functions: Binds with low affinity to interleukin-13 (IL13). Together with IL4RA can form a functional receptor for IL13. Also serves as an alternate accessory protein to the common cytokine receptor gamma chain for interleukin-4 (IL4) signaling, but cannot replace the function of IL2RG in allowing enhanced interleukin-2 (IL2) binding activity
The "IL13RA1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IL13RA1 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
IL13RA2 | IL15 | IL15RA | IL16 | IL17A | IL17B | IL17C | IL17D | IL17F | IL17RA | IL17RB | IL17RC | IL17RD | IL17RE | IL17REL | IL18 | IL18BP | IL18R1 | IL18RAP | IL19 | IL1A | IL1B | IL1F10 | IL1R1 | IL1R2 | IL1RAP | IL1RAPL1 | IL1RAPL2 | IL1RL1 | IL1RL2 | IL1RN | IL2 | IL20 | IL20RA | IL20RB | IL21 | IL21-AS1 | IL21R | IL21R-AS1 | IL22 | IL22RA1 | IL22RA2 | IL23A | IL23R | IL24 | IL25 | IL26 | IL27 | IL27RA | IL2RA | IL2RB | IL2RG | IL3 | IL31 | IL31RA | IL32 | IL33 | IL34 | IL36A | IL36B | IL36G | IL36RN | IL37 | IL3RA | IL4 | IL4I1 | IL4R | IL5 | IL5RA | IL6 | IL6-AS1 | IL6R | IL6R-AS1 | IL6ST | IL6ST-DT | IL6STP1 | IL7 | IL7R | IL9 | IL9R | IL9RP3 | IL9RP4 | ILDR1 | ILDR2 | ILF2 | ILF3 | ILF3-DT | ILK | ILKAP | ILRUN | ILVBL | Imidazoline I2 receptor (I2) | Imidazoline I3 receptor (I3) | Imidazoline receptor | IMMP1L | IMMP2L | IMMT | IMMTP1 | Immunoglobulin A | Immunoglobulin E (IgE)
